|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S1
|
|
$0
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S2
|
$64,741
|
$5,179
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S3
|
$229,232
|
$18,339
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S4
|
$593,811
|
$47,505
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S5
|
$917,771
|
$73,422
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S6
|
$68,356
|
$5,468
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S7
|
$778,576
|
$62,286
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S8
|
$73,651
|
$5,892
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-02
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-02
|
$24,080,302
|
$1,926,424
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Childhood Cancer Survivor Study
|
5U24CA055727-21
|
$4,271,782
|
$427,178
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma
|
5R01CA182633-02
|
$671,686
|
$671,686
|
ASGHARZADEH, SHAHAB
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Cancer Center Support Grant
|
3P30CA082103-17S2
|
$50,000
|
$1,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-17S3
|
$124,967
|
$2,499
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-17S4
|
$199,969
|
$3,999
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-17S5
|
$158,600
|
$3,172
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
5P30CA082103-17
|
$7,292,969
|
$145,859
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA022453-33S1
|
$62,500
|
$5,000
|
BEPLER, GEROLD
|
WAYNE STATE UNIVERSITY
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA022453-33
|
$2,529,146
|
$202,332
|
BEPLER, GEROLD
|
WAYNE STATE UNIVERSITY
|
|
National Center: Multiscale Analysis of Genomic and Cellular Networks (MAGNet)
|
3U54CA121852-10S1
|
$100,000
|
$8,000
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Systems Biology of Tumor Progression and Drug Resistance
|
5U01CA168426-04
|
$1,232,072
|
$1,232,072
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Validating the prognostic value of EGFR768 in neuroblastoma
|
5R21CA187554-02
|
$204,076
|
$204,076
|
CHAN, EDWARD
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
Investigating the tumor suppressive functions of the miR-34 family of microRNAs
|
5F31CA168356-03
|
$43,120
|
$21,560
|
CONCEPCION, CARLA
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-07S1
|
$37,430
|
$374
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-07
|
$1,560,000
|
$15,600
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-39S1
|
$62,498
|
$3,125
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-39S2
|
$125,000
|
$6,250
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-39
|
$7,704,373
|
$385,219
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
MYC--Transcription and Apoptosis
|
5R01CA051497-24
|
$394,000
|
$197,000
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
5R01CA129377-08
|
$239,246
|
$239,246
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Center for Environment-Mediated Drug Resistance in Pediatric Cancer
|
5U54CA163117-05
|
$654,642
|
$477,889
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
|
5R01CA172067-03
|
$324,006
|
$324,006
|
DUBOIS, STEVEN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors
|
1R41CA192656-01
|
$209,001
|
$209,001
|
DURDEN, DONALD
|
SIGNALRX PHARMACEUTICALS, INC.
|
|
Employing the Myc Transcriptional Network to Reveal Oncogenic Pathways
|
5R01CA057138-24
|
$636,692
|
$318,346
|
EISENMAN, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant
|
3P30CA013696-41S1
|
$120,000
|
$4,800
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S2
|
$60,000
|
$2,400
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S3
|
$125,000
|
$5,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-41S4
|
$157,133
|
$6,285
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-41
|
$3,792,720
|
$151,709
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Sphingosine-1-Phosphate Pathway Based Therapy for Neuroblastoma
|
5R01CA168903-04
|
$345,402
|
$345,402
|
FERRER, FERNANDO
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
Molecular determinants of PARP inhibitor sensitivity in 11q-deleted malignancy
|
1R21CA181417-01A1
|
$184,515
|
$92,258
|
FRANCO, SONIA
|
JOHNS HOPKINS UNIVERSITY
|
|
Quantitative SPECT for Targeted Radionuclide Therapy
|
5R01CA109234-10
|
$420,010
|
$105,003
|
FREY, ERIC
|
JOHNS HOPKINS UNIVERSITY
|
|
Epigenetic Regulation of Neuroblast Differentiation
|
1F31CA192558-01
|
$33,544
|
$33,544
|
GAVIGLIO, ANGELA
|
DUKE UNIVERSITY
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
3R01CA148688-05S1
|
$114,997
|
$114,997
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-05
|
$363,125
|
$363,125
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant Year 35 (CCSG)
|
3P30CA021765-36S1
|
$43,749
|
$875
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Cancer Center Support Grant Year 35 (CCSG)
|
3P30CA021765-36S2
|
$130,627
|
$2,613
|
GILBERTSON, RICHARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-40S1
|
$62,500
|
$2,500
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-40S2
|
$50,000
|
$2,000
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
5P30CA014089-40
|
$6,231,178
|
$249,247
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
Total relevant funding to Neuroblastoma for this search: $19,155,625
|